Catalyst Pharmaceutical
CPRX
336 hedge funds and large institutions have $2.04B invested in Catalyst Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 140 increasing their positions, 93 reducing their positions, and 36 closing their positions.
98% more call options, than puts
Call options by funds: $490K | Put options by funds: $248K
64% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 36
51% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 93
7% more capital invested
Capital invested by funds: $1.9B → $2.04B (+$140M)
6% more funds holding
Funds holding: 316 → 336 (+20)
1.43% more ownership
Funds ownership: 80.48% → 81.91% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$28.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$19.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$14.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$10.4M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$66.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$13M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.12M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$8.09M |
| 5 |
Jane Street
New York
|
-$7.83M |
CPRX Hedge Fund Activity: Q4 2024 in Review
336 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2024, worth a combined $2.04B — up 7.4% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new CPRX positions and 36 closed out — a net gain of 23 holders — while 140 added to existing stakes and 93 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $28.6M. The largest seller was Deerfield Management, cutting an estimated $66.5M.
- 336 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2024, up from 316 in Q3 2024.
- Funds reported $2.04B of Catalyst Pharmaceutical stock for Q4 2024, up 7.4% quarter-over-quarter.
- 59 funds opened new Catalyst Pharmaceutical positions in Q4 2024 and 36 closed out, a net change of +23 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2024 was Goldman Sachs, an estimated $28.6M added.
- The largest Catalyst Pharmaceutical seller in Q4 2024 was Deerfield Management, an estimated $66.5M sold.
Based on aggregated 13F filings for Q4 2024.